The US Food and Drug Administration issued 510(k) clearance and a CLIA waiver for Diasorin’s LIAISON Nes four‑plex molecular assay, enabling detection of influenza A/B, RSV and SARS‑CoV‑2 at the point of care. Diasorin said the platform, developed with a major US pharmacy chain, delivers laboratory‑quality PCR results in roughly 15 minutes and uses a three‑step workflow. Carlo Rosa, Diasorin’s CEO, framed the clearance as the company’s entry into molecular POC and a strategic expansion of its diagnostics portfolio. The company said additional infectious‑disease assays are planned for the LIAISON Nes, positioning it as a near‑patient PCR competitor in retail and outpatient settings.